German politicians are considering making COVID-19 mandatory for their citizens, in light of the high incidence of infections and low vaccination rates.
4d Pharma PLC (DDDD.L) Jefferies Next Generation IBD Therapeutics Summit
4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit
4d Pharma PLC (DDDD.L) 4D pharma presents two clinical posters for Live
Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021
4d Pharma PLC (DDDD.L) Two MRx0518 presentations accepted for ESMO 2021
4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021
4d Pharma PLC (DDDD.L) $30 Million Credit Facility with Oxford Finance
Leeds, UK, July 29, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
4d Pharma PLC (DDDD.L) Passing of Chief Financial Officer John Beck
Leeds, UK, July 26, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
4d Pharma PLC (DDDD.L) Publication – LBP improves activity of CAR-T
4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T
Microsaic Systems (MSYS.L) Trading update for H1 2021
Unaudited revenues up 594% on H1 2020 and 52% on H1 2019, reflecting new business model
Microsaic Systems (MSYS.L) Development of real-time monitoring solution
Microsaic demonstrates real-time monitoring for scaling biotherapeutic production Automated system maintains high quality while allowing rapid scaling to large volumes.
4d Pharma PLC (DDDD.L) Conference presentation on LBP Manufacturing
4D pharma to Present at the Microbiome Movement Drug Development Summit
4d Pharma PLC (DDDD.L) Presentations on MRx0518 at SITC 2020
4D pharma announces three presentations at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020
4d Pharma PLC (DDDD.L) Topline Results for Blautix® phase II trial
Positive trends seen in primary efficacy endpoint of the study of overall response in both IBS-C and IBS-D subgroups